Maria R. Milone

Av
Avellino, 83100, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

CLIC2 regulates immunosuppression and macrophage differentiation in genomically stable gastric cancer.

CLIC2 regulates immunosuppression and macrophage differentiation in genomically stable gastric cancer.

Journal: Biology direct

Published: February 19, 2025

The molecular conversations of sarcomas: exosomal non-coding RNAs in tumor's biology and their translational prospects.

The molecular conversations of sarcomas: exosomal non-coding RNAs in tumor's biology and their translational prospects.

Journal: Molecular cancer

Published: July 04, 2024

HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.

HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.

Journal: Molecular oncology

Published: September 23, 2020

Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.

Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 30, 2020

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance.

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance.

Journal: Frontiers in cell and developmental biology

Published: April 01, 2020

Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation.

Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation.

Journal: Journal of experimental & clinical cancer research : CR

Published: April 08, 2019

Novel pathways involved in cisplatin resistance identified by a proteomics approach in non-small-cell lung cancer cells.

Novel pathways involved in cisplatin resistance identified by a proteomics approach in non-small-cell lung cancer cells.

Journal: Journal of cellular physiology

Published: July 11, 2018

Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins.

Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins.

Journal: Recent patents on anti-cancer drug discovery

Published: August 11, 2017

Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.

Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.

Journal: Amino acids

Published: July 18, 2016

Proteomic characterization of peroxisome proliferator-activated receptor-γ (PPARγ) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype.

Proteomic characterization of peroxisome proliferator-activated receptor-γ (PPARγ) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype.

Journal: Molecular oncology

Published: June 14, 2016

Biotin-targeted Pluronic(®) P123/F127 mixed micelles delivering niclosamide: A repositioning strategy to treat drug-resistant lung cancer cells.

Biotin-targeted Pluronic(®) P123/F127 mixed micelles delivering niclosamide: A repositioning strategy to treat drug-resistant lung cancer cells.

Journal: International journal of pharmaceutics

Published: June 06, 2016

Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid.

Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid.

Journal: Oncotarget

Published: May 18, 2015

Showing 1-12 of 14

Last Updated: 09/26/2026